亚太药业(002370) - 2024 Q4 - 年度业绩预告

Financial Performance - The company expects a net profit attributable to shareholders of between RMB 25 million and RMB 37 million for the year 2024, compared to a loss of RMB 11.87 million in the same period last year[2]. - The expected operating revenue for 2024 is between RMB 400 million and RMB 410 million, down from RMB 420.64 million in the previous year[2]. - The company has achieved a turnaround from loss to profit primarily due to receiving a distribution of CAD 2,766,105.25 (approximately RMB 14.11 million) from a joint venture, which increased the total profit for the year[4]. - The company recorded an increase in profit of RMB 38.04 million from reversing previously accrued liabilities related to the equity transfer of Shanghai New Gaofeng Biopharmaceutical Co., Ltd.[4]. - The company will not need to pay the remaining equity transfer payment of RMB 11.25 million, which will be recognized as non-operating income, adding RMB 11.25 million to the total profit for the year[4]. - Excluding non-recurring items, the net profit for the period is expected to decrease by 41.98% to 59.39% compared to the previous year, mainly due to reduced interest expenses and selling costs[5][6]. Audit and Forecast - The company has communicated with its auditing firm regarding the earnings forecast, and there are no significant discrepancies[2].